drugset / Trial / NCT04163783

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

NCT04163783

Phase 1 Completed 6 enrolled BeiGene
NaSingle-groupOpen-labelBasic science

Summary

Phase 1 study in healthy subjects to determine the effect of an 8-hour fast from food on the pharmacokinetics of \[14C\]-BGB-3111.

Timeline

Start
2017-03-29
Primary completion
2017-04-18
Completion
2017-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanubrutinib Small molecule 320 mg Oral

Indications

No indication recorded.